Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection
Background Some biologics for psoriasis, especially anti-tumor necrosis factor (TNF)-α therapies, may re-activate latent tuberculosis (TBC) infection with consequent morbidity and mortality. However, there is a low reported incidence of conversion to positive TBC status among patients with psoriasis...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-07-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2022.2062280 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832095422308417536 |
|---|---|
| author | Matteo Megna Cataldo Patruno Maria Rita Bongiorno Alessio Gambardella Claudio Guarneri Caterina Foti Serena Lembo Francesco Loconsole Gabriella Fabbrocini |
| author_facet | Matteo Megna Cataldo Patruno Maria Rita Bongiorno Alessio Gambardella Claudio Guarneri Caterina Foti Serena Lembo Francesco Loconsole Gabriella Fabbrocini |
| author_sort | Matteo Megna |
| collection | DOAJ |
| description | Background Some biologics for psoriasis, especially anti-tumor necrosis factor (TNF)-α therapies, may re-activate latent tuberculosis (TBC) infection with consequent morbidity and mortality. However, there is a low reported incidence of conversion to positive TBC status among patients with psoriasis treated with second-generation biologic therapies, particularly anti-interleukin (IL)-17 therapies such as secukinumab.Objectives To evaluate the safety profile of secukinumab in psoriasis patients with latent TBC infection.Methods Real-life data were collected by retrospective chart review on patients with moderate-to-severe psoriasis who showed positivity for TBC screening at baseline and underwent secukinumab treatment for psoriasis at six Italian centers. Patients received secukinumab 300 mg at week 0/1/2/3/4, then every 4 weeks.Results Fifty-nine patients were enrolled; 30.5% also had psoriatic arthritis and other comorbidities were common. At baseline, the mean psoriasis duration was 14.5 years. Ten (17%) patients did not undergo prophylaxis before starting secukinumab. Conversely, isoniazid ± rifampicin or rifampicin alone prophylaxis was administered in 49/59 (83.1%) patients. After a mean treatment duration of 84 weeks, there were no cases of TBC reactivation and no unexpected safety signals.Conclusions Secukinumab use over an extended period was safe in psoriasis patients with latent TBC, even in patients who did not receive chemoprophylaxis. |
| format | Article |
| id | doaj-art-cb0cbf4667fd48908e65efb582f4918e |
| institution | Kabale University |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2022-07-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-cb0cbf4667fd48908e65efb582f4918e2025-02-05T19:02:55ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532022-07-013352629263310.1080/09546634.2022.2062280Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infectionMatteo Megna0Cataldo Patruno1Maria Rita Bongiorno2Alessio Gambardella3Claudio Guarneri4Caterina Foti5Serena Lembo6Francesco Loconsole7Gabriella Fabbrocini8Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, ItalyDepartment of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, ItalySection of Dermatology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties “G. D’Alessandro” (PROMISE), University of Palermo, Palermo, ItalyDermatology Unit, University of Campania Luigi Vanvitelli, Naples, ItalyDepartment of Biomedical and Dental Sciences and Morphofunctional Imaging (BIOMORF), Section of Dermatology, University of Messina, Messina, ItalyDepartment of Biomedical Sciences and Human Oncology, Section of Dermatology, University of Bari, Bari, ItalyDepartment of Medicine, Surgery and Dentistry, "Scuola Medica Salernitana" University of Salerno, Salerno, ItalyDepartment of Biomedical Sciences and Human Oncology, Section of Dermatology, University of Bari, Bari, ItalySection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, ItalyBackground Some biologics for psoriasis, especially anti-tumor necrosis factor (TNF)-α therapies, may re-activate latent tuberculosis (TBC) infection with consequent morbidity and mortality. However, there is a low reported incidence of conversion to positive TBC status among patients with psoriasis treated with second-generation biologic therapies, particularly anti-interleukin (IL)-17 therapies such as secukinumab.Objectives To evaluate the safety profile of secukinumab in psoriasis patients with latent TBC infection.Methods Real-life data were collected by retrospective chart review on patients with moderate-to-severe psoriasis who showed positivity for TBC screening at baseline and underwent secukinumab treatment for psoriasis at six Italian centers. Patients received secukinumab 300 mg at week 0/1/2/3/4, then every 4 weeks.Results Fifty-nine patients were enrolled; 30.5% also had psoriatic arthritis and other comorbidities were common. At baseline, the mean psoriasis duration was 14.5 years. Ten (17%) patients did not undergo prophylaxis before starting secukinumab. Conversely, isoniazid ± rifampicin or rifampicin alone prophylaxis was administered in 49/59 (83.1%) patients. After a mean treatment duration of 84 weeks, there were no cases of TBC reactivation and no unexpected safety signals.Conclusions Secukinumab use over an extended period was safe in psoriasis patients with latent TBC, even in patients who did not receive chemoprophylaxis.https://www.tandfonline.com/doi/10.1080/09546634.2022.2062280Biologicschemoprophylaxislatent tuberculosis infectionpsoriasisreactivationsecukinumab |
| spellingShingle | Matteo Megna Cataldo Patruno Maria Rita Bongiorno Alessio Gambardella Claudio Guarneri Caterina Foti Serena Lembo Francesco Loconsole Gabriella Fabbrocini Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection Journal of Dermatological Treatment Biologics chemoprophylaxis latent tuberculosis infection psoriasis reactivation secukinumab |
| title | Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection |
| title_full | Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection |
| title_fullStr | Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection |
| title_full_unstemmed | Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection |
| title_short | Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection |
| title_sort | lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real world setting of latent tuberculosis infection |
| topic | Biologics chemoprophylaxis latent tuberculosis infection psoriasis reactivation secukinumab |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2022.2062280 |
| work_keys_str_mv | AT matteomegna lackofreactivationoftuberculosisinpatientswithpsoriasistreatedwithsecukinumabinarealworldsettingoflatenttuberculosisinfection AT cataldopatruno lackofreactivationoftuberculosisinpatientswithpsoriasistreatedwithsecukinumabinarealworldsettingoflatenttuberculosisinfection AT mariaritabongiorno lackofreactivationoftuberculosisinpatientswithpsoriasistreatedwithsecukinumabinarealworldsettingoflatenttuberculosisinfection AT alessiogambardella lackofreactivationoftuberculosisinpatientswithpsoriasistreatedwithsecukinumabinarealworldsettingoflatenttuberculosisinfection AT claudioguarneri lackofreactivationoftuberculosisinpatientswithpsoriasistreatedwithsecukinumabinarealworldsettingoflatenttuberculosisinfection AT caterinafoti lackofreactivationoftuberculosisinpatientswithpsoriasistreatedwithsecukinumabinarealworldsettingoflatenttuberculosisinfection AT serenalembo lackofreactivationoftuberculosisinpatientswithpsoriasistreatedwithsecukinumabinarealworldsettingoflatenttuberculosisinfection AT francescoloconsole lackofreactivationoftuberculosisinpatientswithpsoriasistreatedwithsecukinumabinarealworldsettingoflatenttuberculosisinfection AT gabriellafabbrocini lackofreactivationoftuberculosisinpatientswithpsoriasistreatedwithsecukinumabinarealworldsettingoflatenttuberculosisinfection |